Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Former Johnson & Johnson Executive Joins MediPharm

Stockhouse Editorial
0 Comments| April 29, 2019

{{labelSign}}  Favorites
{{errorMessage}}

Canadian research-driven cannabis extraction Company MediPharm Labs Inc. (TSX-V: LABS, OTCQB:MLCPF,Forum) had a nice bump in its shares Monday on the news that it has appointed Braden Fenske as Chief Strategy Officer. The former Johnson & JohnsonGroup Product Director will be responsible for advancing the Company’s strategic corporate initiatives in collaboration with the Company’s executives and operational teams across the Company.

For more information on this, click here.

MediPharm was also covered by CFN Media Grouplast week, looking further into its plans for global expansion. This includes its Australian operations and first sale of cannabis oil to an Australian company.


FULL DISCLOSURE: MediPharm Labs Inc. is a client of Stockhouse Publishing.


{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company